Compare Globus Medical Inc. Class A Common Stock (GMED) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Schlumberger NV — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Schlumberger NV trades at $48.64 (market cap $72.38B). The key difference: Schlumberger NV is far larger — about 7.1× Globus Medical Inc. Class A Common Stock's market cap, and Schlumberger NV pays a 2.42% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| GMED | SLB | |
|---|---|---|
Market Cap | $10.25B | $72.38B |
Volume | 1,108,124 | 10,231,115 |
Sector | Health | Energy |
52-Week High | $96.82 | $60.10 |
52-Week Low | $58.33 | $32.57 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $9.76B | $81.11B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SLB trades at $48.51, down 0.53% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with 8.53% net income margin and 13.37% ROE, though revenue declined slightly to $35.71B in 2025. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility. Analyst consensus remains strongly bullish with 85% buy ratings and $64.58 price target representing 33% upside potential.
SLB presents a compelling value opportunity with solid fundamentals and strong analyst support, though near-term headwinds include declining profit margins and bearish technical indicators. The company's recent major contract awards and dividend payments provide stability, but investors should monitor execution risks in international markets and potential volatility in energy sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
